DEPACON (valproate sodium) · AbbVie
DEPACON is FDA-approved to treat 4 conditions (same as VALPROATE SODIUM).
Details
- Status
- Discontinued
- First Approved
- 1996-12-30
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
DEPACON Approval History
What DEPACON Treats
4 indicationsDEPACON is approved for 4 conditions since its original approval in 1996. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Complex partial seizures (monotherapy and adjunctive therapy)
- Simple absence seizures (sole and adjunctive therapy)
- Complex absence seizures (sole and adjunctive therapy)
- Multiple seizure types that include absence seizures (adjunctive therapy)
Same approved indications as VALPROATE SODIUM (same active ingredient).
AbbVie's other novel FDA approvals
Other CDER-designated drugs from the same sponsor (2016–2025).
Clinical Trial Registry
2 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081283 results posted | 23-0157 | Ph 4 | terminated | Antiseizure Medication in Seizure Networks at Early Acute Brain Injury |
| NCT04698525 results posted | 74-19 | Ph 3 | completed | Comparative Study Between Valproate and Memantine in the Prophylactic Management of Episodic Migraine. |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEPACON FDA Label Details
Indications & Usage
FDA Label (PDF)DEPACON is FDA-approved to treat 4 conditions — same approved indications as VALPROATE SODIUM.
Track DEPACON with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.